Mass spectrometry imaging in gynecological cancers: the best is yet to come.
Cancer research
Endometrial cancer
Mass spectrometry imaging
Ovarian cancer
Vulvar cancer
Journal
Cancer cell international
ISSN: 1475-2867
Titre abrégé: Cancer Cell Int
Pays: England
ID NLM: 101139795
Informations de publication
Date de publication:
19 Dec 2022
19 Dec 2022
Historique:
received:
21
09
2022
accepted:
11
12
2022
entrez:
19
12
2022
pubmed:
20
12
2022
medline:
20
12
2022
Statut:
epublish
Résumé
Mass spectrometry imaging (MSI) enables obtaining multidimensional results simultaneously in a single run, including regiospecificity and m/z values corresponding with specific proteins, peptides, lipids, etc. The knowledge obtained in this way allows for a multifaceted analysis of the studied issue, e.g., the specificity of the neoplastic process and the search for new therapeutic targets. Despite the enormous possibilities, this relatively new technique in many aspects still requires the development or standardization of analytical protocols (from collecting biological material, through sample preparation, analysis, and data collection, to data processing). The introduction of standardized protocols for MSI studies, with its current potential to extend diagnostic and prognostic capabilities, can revolutionize clinical pathology. As far as identifying ovarian cancer subtypes can be challenging, especially in poorly differentiated tumors, developing MSI-based algorithms may enhance determining prognosis and tumor staging without the need for extensive surgery and optimize the choice of subsequent therapy. MSI might bring new solutions in predicting response to treatment in patients with endometrial cancer. Therefore, MSI may help to revolutionize the future of gynecological oncology in terms of diagnostics, treatment, and predicting the response to therapy. This review will encompass several aspects, e.g., contemporary discoveries in gynecological cancer research utilizing MSI, indicates current challenges, and future perspectives on MSI.
Identifiants
pubmed: 36536419
doi: 10.1186/s12935-022-02832-3
pii: 10.1186/s12935-022-02832-3
pmc: PMC9764543
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
414Informations de copyright
© 2022. The Author(s).
Références
Int J Mol Sci. 2016 Jul 08;17(7):
pubmed: 27399691
Nat Rev Cancer. 2015 Nov;15(11):668-79
pubmed: 26493647
Biochim Biophys Acta Proteins Proteom. 2017 Jul;1865(7):846-857
pubmed: 27784647
Sci Rep. 2016 Dec 15;6:39219
pubmed: 27976698
Cancer Rep (Hoboken). 2019 Dec;2(6):e1229
pubmed: 32729258
Cancer Res. 2012 Feb 1;72(3):645-54
pubmed: 22139378
Exp Ther Med. 2015 Apr;9(4):1460-1464
pubmed: 25780452
Lab Invest. 2017 Aug;97(8):992-1003
pubmed: 28553935
Anal Bioanal Chem. 2015 Mar;407(8):2035-45
pubmed: 25432304
Proteomics. 2016 Jun;16(11-12):1731-5
pubmed: 27028088
J Am Soc Mass Spectrom. 2006 Dec;17(12):1712-6
pubmed: 16952462
Anal Chem. 2020 Oct 6;92(19):13361-13368
pubmed: 32865977
Front Oncol. 2018 Jun 12;8:225
pubmed: 29946533
Proteomics Clin Appl. 2019 Jan;13(1):e1700181
pubmed: 30471200
Cancers (Basel). 2021 Oct 27;13(21):
pubmed: 34771551
Cell Rep Med. 2021 Sep 23;2(9):100400
pubmed: 34622237
PLoS Med. 2016 Aug 30;13(8):e1002108
pubmed: 27575375
Mass Spectrom Rev. 2021 Aug 15;:
pubmed: 34392557
J Proteome Res. 2013 Apr 5;12(4):1847-55
pubmed: 23480610
Nat Cancer. 2020 Feb;1(2):163-175
pubmed: 35122013
World J Oncol. 2011 Aug;2(4):151-157
pubmed: 29147241
J Cell Biochem. 2012 Dec;113(12):3762-72
pubmed: 22807371
Int J Med Sci. 2011 Apr 20;8(4):287-94
pubmed: 21537492
FASEB J. 2007 Nov;21(13):3419-30
pubmed: 17567567
Health Phys. 2014 Jan;106(1):120-8
pubmed: 24276555
Oncotarget. 2017 May 10;8(32):53819-53828
pubmed: 28881853
Proteomics Clin Appl. 2013 Jun;7(5-6):337-54
pubmed: 23589350
Clin Cancer Res. 2013 Nov 1;19(21):5960-71
pubmed: 24004674
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
Nature. 2015 May 28;521(7553):489-94
pubmed: 26017449
Dis Markers. 2008;25(4-5):219-32
pubmed: 19126966
Nat Methods. 2014 Apr;11(4):417-22
pubmed: 24584193
Proteomics. 2016 Jun;16(11-12):1802-13
pubmed: 27174013
EBioMedicine. 2017 Jul;21:55-64
pubmed: 28629911
Gynecol Oncol. 2020 May;157(2):379-385
pubmed: 32081463
N Engl J Med. 2016 Dec;375(22):2154-2164
pubmed: 27717299
Proteomics. 2019 Nov;19(21-22):e1800482
pubmed: 31364262
Anal Bioanal Chem. 2021 Apr;413(10):2721-2733
pubmed: 33222001
Anal Chem. 2018 Jan 2;90(1):240-265
pubmed: 29155564
Proteomics. 2016 Jun;16(11-12):1793-801
pubmed: 27061135
Cancer Metab. 2014 Jul 17;2:10
pubmed: 25057353
Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5431-6
pubmed: 12702766
Proteomics Clin Appl. 2019 Jan;13(1):e1800064
pubmed: 30311431
Cancers (Basel). 2020 Jul 22;12(8):
pubmed: 32707805
Mol Imaging Biol. 2018 Dec;20(6):888-901
pubmed: 30167993
Nat Med. 2014 Apr;20(4):436-42
pubmed: 24584119
Anal Chem. 2017 Jan 17;89(2):1131-1137
pubmed: 27973782
J Proteome Res. 2012 May 4;11(5):2876-89
pubmed: 22471520
Clin Biochem Rev. 2013 Aug;34(2):43-6
pubmed: 24151340
Mol Cell Proteomics. 2016 Sep;15(9):3003-16
pubmed: 27412689
Gynecol Oncol. 2007 Nov;107(2):266-73
pubmed: 17698176
Br J Cancer. 2020 Jan;122(2):245-257
pubmed: 31819188
Cancers (Basel). 2021 Mar 25;13(7):
pubmed: 33806030
Lab Invest. 2020 Aug;100(8):1124-1136
pubmed: 32341516
N Engl J Med. 2019 Dec 19;381(25):2416-2428
pubmed: 31851799
Anal Chem. 2020 Jan 7;92(1):1301-1308
pubmed: 31793765
Cell. 2006 Sep 8;126(5):855-67
pubmed: 16959566
Acta Biomed. 2019 Dec 23;90(4):405-410
pubmed: 31910163
Medicines (Basel). 2019 Oct 13;6(4):
pubmed: 31614918
PLoS One. 2015 May 07;10(5):e0126444
pubmed: 25951060
Int J Environ Res Public Health. 2020 Oct 18;17(20):
pubmed: 33080944
Pathophysiology. 2019 Sep - Dec;26(3-4):331-341
pubmed: 31564389
Sci Rep. 2019 Jul 23;9(1):10698
pubmed: 31337874
Methods Mol Biol. 2010;656:159-71
pubmed: 20680590
Gynecol Oncol. 2022 Aug;166(2):219-229
pubmed: 35690498
J Am Soc Mass Spectrom. 2021 Apr 7;32(4):977-988
pubmed: 33631930
JAMA Oncol. 2019 Aug 01;5(8):1141-1149
pubmed: 31194228
J Mass Spectrom. 2021 Aug;56(8):e4717
pubmed: 33724654
PLoS One. 2014 Feb 06;9(2):e87978
pubmed: 24516574
J Proteome Res. 2013 Jan 4;12(1):308-15
pubmed: 23214983
Adv Cancer Res. 2017;134:1-26
pubmed: 28110647
Med Sci Monit. 2010 Aug;16(8):BR233-45
pubmed: 20671603
Nature. 2008 Feb 28;451(7182):1111-5
pubmed: 18264088
Int J Cancer. 2006 Jan 15;118(2):412-21
pubmed: 16049973
Cell. 2018 Sep 6;174(6):1373-1387.e19
pubmed: 30193111
Cancers (Basel). 2020 Sep 21;12(9):
pubmed: 32967325
Lancet Oncol. 2019 Oct;20(10):1409-1419
pubmed: 31474354
Onco Targets Ther. 2018 Apr 12;11:2111-2120
pubmed: 29695918
Exp Biol Med (Maywood). 2018 Feb;243(3):213-221
pubmed: 29405771
Glycoconj J. 2012 Dec;29(8-9):567-77
pubmed: 22644327
Proteomics. 2019 Nov;19(21-22):e1900146
pubmed: 31474002
Arch Gynecol Obstet. 2012 Dec;286(6):1537-43
pubmed: 22832979
Proteomics Clin Appl. 2019 Jan;13(1):e1700168
pubmed: 30520240
Semin Cancer Biol. 2021 Dec;77:167-181
pubmed: 32871277
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398
Biomed Res Int. 2015;2015:341723
pubmed: 26075229
Cancers (Basel). 2022 Mar 30;14(7):
pubmed: 35406537
Cancer Res. 2017 Jun 1;77(11):2903-2913
pubmed: 28416487
N Engl J Med. 2019 Dec 19;381(25):2391-2402
pubmed: 31562799
Oncol Rep. 2013 Jan;29(1):58-66
pubmed: 23064469
JAMA Oncol. 2020 Nov 01;6(11):1766-1772
pubmed: 33001143
Nat Med. 2017 Apr;23(4):517-525
pubmed: 28288110